Our proven model for catalysing change
As an independent research foundation, we catalyse change by triggering essential healthcare companies to play their part and raise their game on access. To do so, we use a combination of data, research insights, rankings and report cards, including our influential Access to Medicine Index. In addition, we leverage a network of influential stakeholders, including investors, governments, and the public.
Our tried-and-tested model for change has three key components:
Building consensus on where companies can and should act to improve access to medicine
Every two years, we translate the stakeholder consensus into clear metrics for measuring company behaviour, which we publish in our methodology reports.
Benchmarking companies and stimulating competition by identifying top performers
When companies’ positive actions are publicly recognised, this triggers other companies to join a “race to do well” on priority health targets and topics.
Advocating best practices identified through our research
We engage actively with all stakeholders to facilitate the wider application of best practices and the development of new approaches to long-standing access challenges.
Jayasree K. Iyer, CEO of the Foundation, talking at the expert panel discussion on ‘Future-proofing Health Systems’ at the World Economic Forum - May 2022
Marijn Verhoef, Director of Operations and Research, speaking on the panel ‘Addressing Environmental Aspects of AMR’ at the World AMR Congress in Washington – September 2022
Jayasree K. Iyer, CEO of the Foundation, speaking at CEPI’s Global Pandemic Preparedness Summit as a part of a panel discussion on the topic ‘The Urgency of Now: Planning for the Next Disease X’ – March 2022
Fatema Rafiqi, Research Programme Manager, talking at the expert panel discussion on AMR organized in collaboration with Global Antibiotic R&D Partnership (GARDP) – June 2022
Jayasree K. Iyer, CEO of the Foundation, with Bill Gates and others in a LIVE World Economic Forum expert panel, discussing how new leadership, policy and business models are rewriting the global health playbook – January 2018
We engage directly with key stakeholders
By working alongside stakeholders on systemic access challenges, we can signal where gaps exist and drive the uptake of best practices. The Access to Medicine Foundation’s teams engage directly with pharmaceutical companies, with governments, policy-makers, donors and NGOs and with the investor community.
Large pharmaceutical companies, with their vast resources, portfolios and global reach, have a critical role to play in improving access to medicine. Our company engagement team spurs positive action through direct engagement with pharma companies, in the form of meetings, briefings and workshops. This includes sharing the Foundation’s research results and exploring opportunities and best practices with companies’ leadership and access teams.
Governments and policy-makers have the power to set enabling conditions to facilitate access. Our government engagement team liaises with governments, private foundations, multilateral organisations and non-governmental organisations working to improve global health and access to medicine. By sharing our research findings, we help policy-makers identify key opportunities for collaboration and change-making.
Investors have an influential role regarding the direction of investee companies. Our team helps institutional investors to use the Foundation’s findings and analysis to better manage risks and opportunities for pharmaceutical companies. To date, over 150 investors managing assets of more than USD 25 trillion have committed to use our data and insights.
Our work has a wide impact
Our work has already made a significant contribution to advancing the pharmaceutical industry’s engagement with access issues. Independent third-party evaluation has confirmed the validity of our three-part model for change and the effectiveness of the mechanisms we use to mobilise the healthcare industry to improve access.
Our Access to Medicine Index is the most comprehensive, long-running survey of company behaviour regarding access to medicine, and the primary benchmark of its kind. As a tool for learning and discussion, the Index helps companies understand the scope of their own activities and how to implement best practices, while stimulating healthy competition between firms to do better.
We are committed to making all our findings freely and publicly available. By openly publishing our data on company behaviour, we contribute to greater transparency in the pharmaceutical industry, empowering change from within. Meanwhile, armed with our insights, policy-makers and investors are able to make better-informed decisions about how to engage with healthcare companies for the greater good.